98%
921
2 minutes
20
Backgrounds/aims: Challenges arise when translating pure laparoscopic donor right hepatectomy (PLDRH) results from Asian to Western donors, due to differences in body mass index (BMI). This study compares the outcomes of PLDRH and conventional open donor right hepatectomy (CDRH) in donors with BMI over 30.
Methods: Medical records of live liver donors (BMI > 30) undergoing right hepatectomy (2010-2021) were compared: 25 PLDRH cases vs. 19 CDRH cases. Donor and recipient demographics, operative details, and outcomes were analyzed.
Results: PLDRH and CDRH had similar donor and recipient characteristics. PLDRH had longer liver removal and warm ischemic times, but a shorter post-liver removal duration than CDRH. Donor complication rates were comparable, with the highest complication being grade IIIa in PLDRH, necessitating needle aspiration for biloma on postoperative day 11. Fortunately, this donor fully recovered without additional treatment. No complications exceeding Clavien-Dindo grade IIIa occurred in either group. Recipient outcomes between the groups were similar.
Conclusions: This study supports PLDRH as a viable option for donors with BMI over 30, challenging the notion that high BMI should deter considering PLDRH. The findings provide valuable insights into the safety and feasibility of PLDRH, encouraging further exploration of this technique in diverse donor populations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11341885 | PMC |
http://dx.doi.org/10.14701/ahbps.24-020 | DOI Listing |
Glob Health Med
August 2025
National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Liver resection (LR) remains a cornerstone curative option for patients with hepatocellular carcinoma (HCC), and yet the high rate of postoperative intrahepatic recurrence poses a significant clinical challenge. Despite numerous attempts, no adjuvant therapy has shown definitive efficacy in preventing recurrence. In this context, salvage liver transplantation (SLT) and repeat hepatectomy (RH) have emerged as key curative strategies for recurrent disease.
View Article and Find Full Text PDFHepatobiliary Surg Nutr
August 2025
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences (CAMS), Beijing, China.
Clin Transplant
September 2025
Department of Anesthesiology and Reanimation, Istanbul Medipol University, Istanbul, Turkey.
Background: Optimal postoperative pain management in living donor hepatectomy remains challenging, with conventional methods showing limitations. This study evaluated the efficacy and safety of ultrasound-guided modified thoracoabdominal nerve block through a perichondrial approach (M-TAPA) compared to conventional pain management in living donor hepatectomy patients.
Methods: In this prospective, randomized, controlled, single-blind study conducted between April 2024 and January 2025, 50 ASA I-II patients undergoing living donor right hepatectomy were randomly allocated to either the M-TAPA group (n = 25, receiving ultrasound-guided M-TAPA block plus standard analgesia) or the Control group (n = 25, receiving conventional pain management only).
Pediatr Transplant
November 2025
Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.
Background: Liver transplantation (LT) has been recommended for hepatoblastoma (HB) involving all four liver sectors at diagnosis (PRETEXT IV). However, recent studies question the universal indication for primary LT in PRETEXT IV HB.
Methods: We reviewed 32 PRETEXT IV HB patients treated at our center from February 2007 to July 2024.
Dig Liver Dis
August 2025
Department of General, Visceral, Vascular and Transplantation Surgery, University Hospital Essen, Essen, Germany.
Background: Although liver transplantation (LT) is highly complicated, its surgical difficulty was to date not defined. A point-based system, considering cold ischemia, blood transfused, and surgery time, showed promising results in short-term outcomes.
Aims: We aimed to validate this model in the Eurotransplant region and to combine donor and recipient data to highlight high-risk candidates.